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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of evidence. 
How many are at increased risk of severe COVID-19 disease? Rapid global, regional and 
national estimates for 2020 
Clark et al | CMMID LSHTM | 14 April 2020 | Study not yet peer reviewed 
https://cmmid.github.io/topics/covid19/severity/Global_risk_factors.html 
There is a need to understand how the number of individuals at risk of severe COVID-19 illness 
varies between countries to inform the design of possible strategies to shield those at highest risk. 
Based on current guidelines and prevalence data from GBD, this study estimates that 1.7 (1.0 to 
2.4) billion individuals (22% [15 to 28%] of the global population) are at increased risk of severe 
COVID-19 disease. This ranges from 16% of the population in Africa to 31% in Europe. Chronic 
kidney disease, cardiovascular disease, diabetes and chronic respiratory disease were the most 
prevalent conditions in males and females. African countries with a high prevalence of HIV/AIDS 
have a high share of the population at increased risk. For many of these individuals, the underlying 
condition will be undiagnosed and the increase in risk maybe quite modest. Analyses of the risks 
associated with different underlying conditions is needed to enable countries to be able to identify 
the highest risk groups to develop targeted shielding policies. 
Three lessons for the COVID-19 response from pandemic HIV 
Hargreaves, J. & Davey, C. | The Lancet HIV | 13 April 2020 | Comment 
https://doi.org/10.1016/S2352-3018(20)30110-7 
Three critical lessons from the HIV pandemic can be applied to the COVID-19 pandemic. (1) 
anticipate health inequalities – the global burden of COVID-19 will likely hit older people and 
vulnerable groups in LMICs yet we must aim to leave no one behind. We must track the 
socioeconomic status and gender of those affected and track economic impacts. (2) Create an 
enabling environment to support behaviour change. In the short-term pragmatic responses will be 
needed such as rapid mass distribution of soap, sanitiser and PPE where there is scarcity of clean 
water. Building social capital, trust and community cohesion and supporting local leadership will 
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have greater health messaging impact, avoid unintended social consequences (e.g. stigma) and 
address social upheaval. (3) The response must be multidisciplinary from epidemiological models 
predicting the dynamics of the pandemic to implementation of healthcare and social delivery.  
COVID-19 Therapeutics Accelerator 
https://www.therapeuticsaccelerator.org 
A philanthropic initiative designed to coordinate R&D efforts, develop and bring effective 
treatments to market quickly and accessibly. 
COVID-19: Gavi steps up response to the pandemic 
GAVI | 9 April 2020 | News 
https://www.gavi.org/news/media-room/covid-19-gavi-steps-response-pandemic 
Includes an infographic on Gavi funding for the COVID-19 response so far. 
Online learning and events 
Emerging respiratory viruses, including COVID-19: methods for detection, prevention, 
response and control 
WHO | Free | 3 hours duration  
https://openwho.org/courses/introduction-to-ncov 
A general introduction to enable you to describe the fundamental principles of emerging 
respiratory viruses, including novel coronaviruses, and how to effectively respond to an outbreak. 
Intended for public health professionals, incident managers and personnel working for the UN, 
international organisations and NGOs. 
Responding to COVID-19: Real-time training for the coronavirus disease outbreak 
WHO | Available now | multiple self-paced courses 
https://openwho.org/channels/covid-19 
Note that courses are available in English and other languages including French, Portuguese 
and Spanish. 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 25 May 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
Unfacilitated access to this course remains. An updated version of this course will though be run 
from 25 May 2020. On this course you will learn what is known about the outbreak of COVID-19 
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(week 1); what the practical implications for responding to COVID-19 are (week 2); and what we 
need to find out about COVID-19 (week 3). 
COVID-19 Diagnostics and Testing 
FIND, LSHTM & ASLM | FutureLearn course | Starts 20 April 2020 | 3 weeks | 3 hours weekly 
study | Free 
https://www.futurelearn.com/courses/covid-19-diagnostics-and-testing 
This course is designed for professionals involved in the testing and diagnosis of COVID-19, with 
a focus on low- and middle-income settings. You will learn the latest recommendations on COVID-
19 testing, get upt0date information on the performance of tests and how best to deploy them. 
COVID-19 Critical Care: Understanding and Application 
University of Edinburgh & Royal College of Physicians of Edinburgh  | FutureLearn course | 
Starts 6 April 2020 | 5 weeks | 1 hour weekly study | Free 
https://www.futurelearn.com/courses/covid-19-critical-care-education-resource 
Designed for frontline clinical staff to learn the principles and practice of critical care to treat and 
care for critically ill patients during the COVID-19 pandemic. You will learn (1) how to apply the 
current and evolving principles of PPE in the care of COVID-19; (2) apply evidence-based 
principles of advanced organ support and monitoring to the COVID-19 critically ill patients; (3) 
apply evidence-based daily practices to care of the critically ill patient; and (4) develop a range of 
specialised self-caring practices. 
Note that this resource has been created in response to the COVID-19 emergency and does not 
correspond to the classic structure of a FutureLearn course. You do not have to follow the week 
by week approach and can select the materials most relevant to your work. 
Tracking Dashboards 
Global WHO sitreps 
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 WEF 
 Vaccine Centre LSHTM 
 Our World in Data 
 Global 5050 
 Humanitarian Data Exchange 
 Information is Beautiful 
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Regional  WHO Africa  
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 European CDC 
Country Ghana 
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 Singapore 
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Guidelines 
Global WHO 
Regional Africa CDC 
Country Nigeria CDC 
 UK Government 
 UK ONS 
 NICE UK 
 US CDC 
Resource Hubs 
Multilaterals WHO 
 WHO risk communication 
 WHO Q&A 
 WHO Global research 
 UN 
 UN Women 
 UNOCHA 
 UNICEF 
 UNESCO 
 UN WFP 
 World Bank 
Regional & Country Africa CDC 
Academic journals The Lancet 
 NEJM 
 Elsevier 
 BMJ 
 Cell 
 PLoS 
 Cochrane reviews 
Global Health Institutes LSTM 
 LSHTM 
 Johns Hopkins University 
 ICL MRC Centre for Global Infectious Disease Analysis  
 ODI 
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 Norwegian Institute of Public Health 
Ethics Rings HSG Resyst Reach Wellcome  
Clinical trials US NIH registered clinical trials  
Funding bodies UKRI 
 Wellcome 
Demographics WorldPop 
Global Impact Surveys Premise COVID-19 Global Impact Study 
 GeoPoll: SSA 
TB Stop TB Partnership 
Disability IDA 
 Disability and inclusion 
 Coregroup IDDC  
SDGs Global Partnership for Sustainable Development Data  
Humanitarian Reliefweb 
 Humanitarian OpenStreetMap Team  
 SSHAP 
Narratives David Nabarro, WHO DG Special Envoy on COVID-19 
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About this report 
This daily COVID-19 health evidence summary is based on 3 hours of desk-based research. K4D services are 
provided by a consortium of leading organisations working in international development, led by the Institute of 
Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield Centre for 
International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of Birmingham 
International Development Department (IDD) and the University of Manchester Humanitarian and Conflict 
Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for International 
Development (DFID) and its partners in support of pro-poor programmes. It is licensed for non-
commercial purposes only. K4D cannot be held responsible for errors, omissions or any 
consequences arising from the use of information contained in this health evidence summary. 
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